{
    "organizations": [],
    "uuid": "b53eb14bdc3d7c060dc8fa3798d5c46f20688650",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-sanofi-cfo-sees-commercial-cost-an/brief-sanofi-cfo-sees-commercial-cost-and-tax-synergies-following-bioverativ-deal-idUSP6N1KG003",
    "ord_in_thread": 0,
    "title": "BRIEF-Sanofi CFO sees commercial, cost and tax synergies following Bioverativ deal",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Jan 22 (Reuters) - Sanofi Chief financial officer Jerome Contamine says :\n* sees commercial, cost and tax synergies related to the acquisition of U.S firm Bioverativ by Franceâ€™s Sanofi Further company coverage: (Paris Newsroom)\n ",
    "published": "2018-01-22T21:46:00.000+02:00",
    "crawled": "2018-01-23T18:16:49.035+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "jan",
        "reuters",
        "sanofi",
        "chief",
        "financial",
        "officer",
        "jerome",
        "contamine",
        "say",
        "see",
        "commercial",
        "cost",
        "tax",
        "synergy",
        "related",
        "acquisition",
        "firm",
        "bioverativ",
        "france",
        "sanofi",
        "company",
        "coverage",
        "paris",
        "newsroom"
    ]
}